间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
癌症仍是一个关键的全球健康问题,原因在于发现晚、耐药和高死亡率。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Gastric cancer with microsatellite instability displays increased thymidylate synthase expression.
Gastric cancer with microsatellite instability displays increased thymidylate synthase expression.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
MSI GC 与高 TS 水平相关,这可能解释了对 5-FU 的治疗耐药。此外,MSI + TS-high 显示出更好的生存,但 CMT 并未带来改善。
微卫星不稳定(MSI)的胃癌(GC)是一种侵袭性较低的疾病,并且与对基于5-氟尿嘧啶(5-FU)的化疗(CMT)耐药相关。胸苷酸合成酶(TS)被5-FU抑制,并且是5-FU治疗耐药的另一个潜在介质。因此,我们旨在分析GC中MSI与TS表达之间的关联及其对疾病结局的影响。
我们回顾性评估了接受D2胃切除术的GC患者。通过免疫组织化学分析MSI和TS。我们还研究了p53表达、PD-L1状态和TIL(肿瘤浸润淋巴细胞)(CD4和CD8)。
在284例GC中,60例(21.1%)为MSI。所有病例的中位TS-score为16.5。与微卫星稳定(MSS)相比,MSI中TS表达显著更高(p < 0.001)。结合两种状态,GC被分为四组:167例(58.8%)MSS + TS-low;57例(20.1%)MSS + TS-High;24例(8.5%)MSI + TS-low;以及36例(12.7%)MSI + TS-high。MSI + TS-high组具有较少的晚期pTNM分期、更高的CD8+T细胞水平(p < 0.001)和PD-L1阳性(p < 0.001)。正常p53表达与MSI GC相关(p < 0.001)。在MSI + TS-high中观察到生存改善,但CMT未见生存获益。
Gastric cancer (GC) with microsatellite instability (MSI) is a less aggressive disease and associated with resistance to 5-fluorouracil (5-FU)-based chemotherapy (CMT). Thymidylate synthase (TS) is inhibited by 5-FU, and another potential mediator of therapeutic resistance to 5-FU. Therefore, we aimed to analyze the association between MSI and TS expression in GC, and its impact on disease outcomes.
We retrospectively evaluated GC who underwent D2-gastrectomy. MSI and TS were analyzed by immunohistochemistry. We also investigated p53 expression, PD-L1 status, and tumor-infiltrating lymphocytes (CD4 and CD8).
Out of 284 GC, 60 (21.1%) were MSI. Median TS-score for all cases was 16.5. TS expression was significantly higher in MSI compared to microsatellite-stable (MSS; p < 0.001). Considering both status, GC were classified in four groups: 167 (58.8%) MSS + TS-low; 57 (20.1%) MSS + TS-High; 24 (8.5%) MSI + TS-low; and 36 (12.7%) MSI + TS-high. MSI + TS-high group had less advanced pTNM stage, higher CD8+T cells levels (p < 0.001) and PD-L1 positivity (p < 0.001). Normal p53 expression was related to MSI GC (p < 0.001). Improved survival was observed in MSI + TS-high, but no survival benefit was seen with CMT.
MSI GC was associated with high TS levels, which may explain therapeutic resistance to 5-FU. Additionally, MSI + TS-high showed better survival, but without improvement with CMT.
MEMBER ACCOUNT
登录成功会直接打开下一页。